Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Inarctica became a co-owner of the project company

5/29/23 AQUA

Big Lots reported for 3 months of 2023

5/26/23 BIG

Board of Directors of Softline JSC approved the prospectus of the company's ordinary shares

5/26/23 SFTL

QIWI reported for 3 months of 2023 by IFRS

5/26/23 QIWI

TCS Group has the financial capacity to pay dividends, but not the technical capacity

5/26/23 T

Rosseti Moscow Region reported for 3 months of 2023 by IFRS

5/26/23 MSRS

Svetofor reported for 3 months of 2023 by RAS

5/26/23 SVET

MKB reported for 3 months of 2023 by IFRS

5/26/23 CBOM

Board of Directors of OGK-2 recommended that dividends be paid for 2022

5/26/23 OGKB

Board of Directors of Phosagro recommended that dividends be paid for 3 мес. 2023

5/26/23 PHOR